Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey A Carter

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Clinical Lung Cancer|April 2, 2013
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutationsAnish Thomas, Liqiang Xi, Corey A Carter, et al.
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Case Reports in Oncology|March 3, 2016
Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of EpisensitizationCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 14, 2018
Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER PopulationJie Lin, Christine Kamamia, Derek Brown, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health SystemJie Lin, Corey A Carter, Katherine A McGlynn, et al.
Case Reports in Oncology|March 3, 2016
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case ReportChristina Brzezniak, Bruno A Schmitz, Paul G Peterson, et al.
Annals of Epidemiology|September 21, 2021
Comparative study of survival among small cell lung cancer patients in the U.S. military health system and those in the surveillance, epidemiology, and end results (SEER) programJie Lin, Christine Kamamia, Derek W Brown, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Oncotarget|March 24, 2016
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapiesCorey A Carter, Karen Zeman, Regina M Day, et al.
Clinical Lung Cancer|April 2, 2013
Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutationsAnish Thomas, Liqiang Xi, Corey A Carter, et al.
Case Reports in Oncology|November 25, 2015
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine TumorCorey A Carter, Aiste Degesys, Bryan Oronsky, et al.
Frontiers in Oncology|February 13, 2015
The war on cancer: a military perspectiveBryan Oronsky, Corey A Carter, Vernon Mackie, et al.
Neoplasia (New York, N.Y.)|October 18, 2015
Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-DistanceBryan Oronsky, Corey A Carter, Tony R Reid, et al.
Case Reports in Oncology|March 3, 2016
Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of EpisensitizationCorey A Carter, Bryan T Oronsky, Scott Z Caroen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 14, 2018
Survival among Lung Cancer Patients in the U.S. Military Health System: A Comparison with the SEER PopulationJie Lin, Christine Kamamia, Derek Brown, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2015
A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health SystemJie Lin, Corey A Carter, Katherine A McGlynn, et al.
Case Reports in Oncology|March 3, 2016
RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case ReportChristina Brzezniak, Bruno A Schmitz, Paul G Peterson, et al.
Annals of Epidemiology|September 21, 2021
Comparative study of survival among small cell lung cancer patients in the U.S. military health system and those in the surveillance, epidemiology, and end results (SEER) programJie Lin, Christine Kamamia, Derek W Brown, et al.
Pageof 6